<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OPINION STATEMENT: <z:hpo ids='HP_0001635'>Congestive heart failure</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>) is associated with an increased risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> mainly due stasis leading to increased risk of <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation in the left ventricle and subsequent <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> patients are also at increased risk of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF) that also leads to <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Aggressive medical management to prevent <z:e sem="disease" ids="C0018802" disease_type="Disease or Syndrome" abbrv="CHF|chf">cardiac decompensation</z:e> and maintain sinus rhythm is indicated in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> and AF should be anticoagulated with <z:chebi fb="8" ids="10033">warfarin</z:chebi> or one of the newer oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>There is no clear indication for anticoagulation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> patients due to ischemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> who are in sinus rhythm </plain></SENT>
<SENT sid="5" pm="."><plain>Based on data from the WARCEF study (see below), those patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> due to non-ischemic etiologies who are in sinus rhythm and have a left ventricular ejection fraction (LVEF) less than 30 % to 35 % may benefit from <z:chebi fb="8" ids="10033">warfarin</z:chebi> for the reduction of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> risk, but <z:chebi fb="8" ids="10033">warfarin</z:chebi> does not increase survival </plain></SENT>
<SENT sid="6" pm="."><plain>Whether <z:chebi fb="8" ids="10033">warfarin</z:chebi> is particularly beneficial for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> patients who have a prior history of <z:hpo ids='HP_0001297'>stroke</z:hpo> or <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> (<z:hpo ids='HP_0002326'>TIA</z:hpo>) is unknown </plain></SENT>
<SENT sid="7" pm="."><plain>If, however, there is high enough suspicion that the <z:hpo ids='HP_0001297'>stroke</z:hpo> was of cardioembolic origin in patients with low LVEF, then anticoagulation would possibly be a reasonable option for prevention of recurrent <z:hpo ids='HP_0001297'>stroke</z:hpo> or <z:hpo ids='HP_0002326'>TIA</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="8" ids="10033">Warfarin</z:chebi> is indicated for <z:hpo ids='HP_0001297'>stroke</z:hpo> prophylaxis among those <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> patients who have an implanted mechanical device </plain></SENT>
<SENT sid="9" pm="."><plain>The role of newer <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> who do not have AF is unknown at this time </plain></SENT>
<SENT sid="10" pm="."><plain>Theoretically, there should be no reason against using these agents in place of <z:chebi fb="8" ids="10033">warfarin</z:chebi> in selected patients, particularly those with highly variable International Normalized Ratios (INR) in the context of <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy, but the newer <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> have not yet been studied among <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> patients without concomitant AF </plain></SENT>
</text></document>